TESARO (NASDAQ:TSRO) had its price target reduced by Morgan Stanley from $165.00 to $156.00 in a report published on Tuesday morning, Marketbeat.com reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

TSRO has been the topic of several other reports. Barclays started coverage on TESARO in a research report on Monday, October 23rd. They issued an equal weight rating and a $135.00 price target on the stock. ValuEngine downgraded TESARO from a hold rating to a sell rating in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a hold rating and issued a $124.00 price target on shares of TESARO in a research report on Friday, November 3rd. HC Wainwright reaffirmed a buy rating and issued a $158.00 price target on shares of TESARO in a research report on Thursday, October 26th. Finally, Robert W. Baird reissued a neutral rating and set a $125.00 price objective on shares of TESARO in a report on Monday, October 2nd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. TESARO currently has an average rating of Hold and a consensus price target of $149.97.

TESARO (NASDAQ TSRO) opened at $63.91 on Tuesday. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $3,453.25, a P/E ratio of -7.57 and a beta of 1.51. TESARO has a 1 year low of $59.77 and a 1 year high of $192.94.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The company’s revenue for the quarter was up 740.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.72) EPS. equities analysts anticipate that TESARO will post -8.19 earnings per share for the current year.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. 40.50% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue acquired a new stake in TESARO in the 4th quarter valued at $223,000. Fox Run Management L.L.C. acquired a new stake in TESARO in the 4th quarter valued at $218,000. Creative Planning boosted its stake in TESARO by 23.1% in the 4th quarter. Creative Planning now owns 50,209 shares of the biopharmaceutical company’s stock valued at $4,161,000 after buying an additional 9,432 shares in the last quarter. Gateway Investment Advisers LLC boosted its stake in TESARO by 30.2% in the 4th quarter. Gateway Investment Advisers LLC now owns 25,937 shares of the biopharmaceutical company’s stock valued at $2,149,000 after buying an additional 6,016 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in TESARO by 27.2% in the 4th quarter. Bank of Montreal Can now owns 9,103 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 1,948 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://theolympiareport.com/2018/01/20/tesaro-tsro-price-target-cut-to-156-00-by-analysts-at-morgan-stanley.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.